

DIVI'S LABORATORIES LIMITED

AUDITED FINANCIAL RESULTS
FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2008

(Rs.in Lakhs)

		STAND ALONE				
	Particulars	9 Months ended 31.12.2007	Quarter ended 31.03.2008	Quarter ended 31.03.2007	Audited for the Year Ended 31.03.2008	Audited for the Year Ended 31.03.2007
		(1)	(2)	(3)	(4)	(5)
1	Net Sales/Income from operations (Net of Excise Duty)	75480	27839	25259	103319	72442
2	Other Income	949	412	340	1361	1361
3	<u>Total Income:</u>	76429	28251	25599	104680	73803
4	<u>Expenditure:</u>					
	a. (Increase) / Decrease in Stock	(2268)	(951)	(907)	(3219)	1198
	b. Consumption of Raw Material	33260	11128	9873	44388	31112
	c. Purchase of Traded Goods	0	0	0	0	0
	d. Staff Cost	3597	1457	1850	5054	5158
	e. Depreciation	2549	1016	804	3565	2233
	f. Other Expenditure					
	- Manufacturing Expenses	4880	1571	1372	6451	4381
	- Other expenses	5875	3079	1682	8954	5994
	Total	47893	17300	15080	65193	50076
5	Finance charges	835	183	406	1018	1057
6	Exceptional items	0	0	0	0	0
7	<u>Profit from ordinary activities before Tax (3-4+5+6)</u>	27701	10768	10519	38469	22670
8	Tax Expense					
	- Current Tax	2960	874	545	3834	3332
	- MAT Credit Entitlements	(1863)	(67)	0	(1930)	0
	- Deferred Tax	666	511	(135)	1177	137
	- Fringe Benefit Tax	19	13	11	32	27
9	<u>Net Profit from ordinary activities after Tax: (7-8)</u>	25919	9437	10098	35356	19174
10	Extra-ordinary items (net of tax expense)	0	0	0	0	0
11	Net Profit for the period (9-10)	25919	9437	10098	35356	19174
12	Paid-up Equity Share Capital (Face Value : Rs.2 per share)	1291	1291	1291	1291	1291
13	Reserves excluding revaluation reserves				86107	52913
14	Earnings per Share:					

a)	Basic Earnings Per Share before extra-ordinary items Rs.	40.15	14.62	15.75	54.77	29.91
	Diluted Earnings Per Share before extra-ordinary items Rs.	39.69	14.45	15.56	54.14	29.55
b)	Basic Earnings Per Share after extra-ordinary items Rs.	40.15	14.62	15.75	54.77	29.91
	Diluted Earnings Per Share after extra-ordinary items Rs.	39.69	14.45	15.56	54.14	29.55
15	Aggregate of non-promoter shareholding					
	- No. of shares	29992600	29972600	29992100	29972600	29992100
	- Percentage of shareholding	46.46%	46.43%	46.46%	46.43%	46.46%

NOTES:

- The above results for the quarter and period ended 31st March 2008, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 7th June, 2008.
- The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
- Other Expenses include an amount of Rs.988 lakhs towards loss on forex fluctuations and forward hedging/swap arrangements.
- Nutraceuticals Manufacturing facility with the beadlet technology has been commissioned and commenced commercial operations effective 1st June, 2008.
- The Board of Directors of the company has recommended a dividend of 200% on the equity shares, subject to approval of members.
- The figures for the previous year/period have been regrouped or recasted, wherever necessary.
- Consolidated Financial Results of the company with its subsidiaries M/s.Divis Laboratories (USA) Inc and M/s.Divi's Laboratories Europe AG are given below:

Rs.lakhs						
	Particulars	Period ended 31.12.2007	Quarter ended 31.03.2008	Quarter ended 31.03.2007	Year Ended 31.03.2008	Year Ended 31.03.2007
1	Turnover	75469	27814	25266	103283	72458
2	Net Profit after tax	25492	9267	9893	34759	18586
3	Earnings Per Share (Face Value Rs.2 each)					
	Basic: Rs.	39.49	14.35	15.43	53.84	28.99
	Diluted: Rs.	39.03	14.20	15.25	53.23	28.65

- Details of Investor complaints pursuant to Clause 41 of the Listing Agreement for the quarter ended 31.03.2008:
Opening: Nil, Received during the Quarter: 4, Resolved: 4, Closing: Nil

for Divi's Laboratories Limited

Place: Hyderabad
Date: 7th June, 2008

Dr. Murali K. Divi
Chairman & Managing Director